Search clinical trials for: MRKAd5 HIV-1 gag vaccine (V520)

Total 97 results

Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
Merck Sharp & Dohme LLC

Terminated

Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

HIV Infections
Merck Sharp & Dohme LLC

Completed

MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC
HIV Vaccine Trials Network

Terminated

Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)

HIV Infections | AIDS
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group; Acute Infection and Early Disease Research Program

Completed

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

HIV Infections

United States, American Samoa, Australia
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults

HIV Infections

South Africa
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

HIV-1 Infection
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

HIV Infections

United States, Thailand
Barbara Ensoli, MD
Novartis Vaccines

Terminated

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

HIV Infection

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

HIV Infections

United States
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Active, not recruiting

Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Condylomata Acuminata
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Unknown

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

HIV Infections

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

HIV Infections

United States
California State University, Long Beach
National Institute on Drug Abuse (NIDA)

Completed

Behavioral Science Aspects of Rapid Test Acceptance (BSARTA)

Hepatitis B | Hepatitis C | HIV | Syphilis

United States
Institute of Medical Biology, Chinese Academy of...
Jiangsu Province Centers for Disease Control and Prevention

Completed

The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines (HAV)

Hepatitis A

China
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Terminated

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

HIV Infections

United States, Brazil
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)

Cervical Cancer | HPV | Premalignancy Anogenital Warts
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; MicroGeneSys Inc (nka Protein Sciences Corporation)

Completed

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

HIV Infections

United States, Puerto Rico
Sharon Riddler
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Autologous Dendritic Cell Vaccine in HIV1 Infection

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Lederle-Praxis Biologicals

Completed

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Genital Warts | Human Papilloma Virus
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Suspended

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

HIV Infections

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
GlaxoSmithKline

Completed

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

Infections, Streptococcal

Germany, Czechia, Sweden, Poland
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

HIV Infections

United States, Brazil, Haiti, Jamaica, South Africa
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
Novartis Vaccines

Completed

Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Influenza

Lithuania
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
National Cancer Institute (NCI)

Terminated

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Melanoma

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico

3

Subscribe